Target Audience
This activity has been designed to meet the educational needs of gastroenterologists and other healthcare providers involved in the care of patients with irritable bowel syndrome (IBS).
Educational Objectives
Upon completing this program, participants should be better able to:
Incorporate into clinical practice novel diagnostic tools to differentiate IBS from other common disorders and make a "positive" IBS diagnosis
Individualize nonpharmacologic treatment plans for IBS patients using evidence-based recommendations
Individualize pharmacologic treatment plans for IBS patients using evidence-based recommendations
For more information, email us at info@GiHealthFoundation.org, or call 1-877-782-4532.
(select a speaker to view their bio and disclosure)
01:53 Introduction and Breaking Stories From DDW 2016
Advances in Symptom-Based Diagnosis of IBS (Rome IV Update)
Patient With Abdominal Discomfort and Chronic, Severe Diarrhea
Integrating Novel Diagnostic Strategies Into Clinical Practice: Serologic testing for post-infectious IBS, new tests for sucrase and lactase deficiency, and anorectal manometry
Facilitating Patient-Physician Communication About GI Symptoms:
MyGiHealth Mobile App
Patient With IBS-D Symptoms
Advances in Nonpharmacologic Treatment of IBS-D: Evidence-based use of FODMAPs, nutritional supplements, peppermint oil, and probiotics
Advances in Pharmacologic Treatment of IBS-D: Evidence-based use of rifaximin, eluxadoline, and ondansetron with conventional therapies
01:18:39 Panel Discussion and Q&A
01:24:33 Closing Remarks
This program is not affiliated with Digestive Disease Week®.
Supported by educational grants from Commonwealth Laboratories, LLC., and QOL Medical, LLC.
Provided by:
William D. Chey, MD, received his BA degree from the University of Pennsylvania and medical degree & training in internal medicine at the Emory University School of Medicine. He completed a fellowship in gastroenterology at the University of Michigan in Ann Arbor. Following fellowship, Dr Chey has remained at the University of Michigan, where he is currently the Timothy T. Nostrant Collegiate Professor of Gastroenterology, Director-GI Physiology Laboratory, Co-Director-Michigan Bowel Control Program, and Director-GI Nutrition & Behavioral Wellness Program. In 2011, Dr. Chey was named as an H. Marvin Pollard Institute Scholar at the University of Michigan. He was awarded a joint appointment in the Department of Nutrition Sciences in 2015.
His research interests focus on the diagnosis & treatment of functional bowel disorders, acid-related disorders, and H. pylori infection. Dr Chey has been funded by federal and private sources. He is a medical innovator and holds 4 patents. He co-founded "My Total Health", a company developing novel health information technology solutions for persons with GI problems.
Dr Chey has authored more than 350 manuscripts, reviews, chapters & books. He served as Co-editor-in-Chief of the American Journal of Gastroenterology (2010-2015), founding co-EIC of Clinical & Translational Gastroenterology (2011-2014). He is leading the update of the ACG H. pylori practice guideline and participating in creation of an AGA technical review on the diagnosis of IBS-D.
Dr. Chey is a member of the Board of Trustees of the American College of Gastroenterology and joined the Board of Directors of the ACG Institute in 2014. He is a member of the Board of Directors of the Rome Foundation and is on the editorial board for the Rome IV criteria.
He has been elected to "Best Doctors" since 2001 and "America's Top Doctors" since 2009. In 2015, Dr. Chey was named as one of the "190 Gastroenterologists to Know" by Becker's ASC. In 2014, Dr. Chey was inducted into the Clinical Excellence Society of the Department of Medicine, received the Dean's Outstanding Clinician Award, and was inducted into the League of Research Excellence at the University of Michigan. In 2015, he was inducted into the League of Clinical Excellence at UM and received the Distinguished Clinician Award from the American Gastroenterological Association.
Consultant/Speaker Bureau: Actavis, Ardelyx, AstraZeneca, IMHealthScience, Ironwood Pharmaceuticals, Inc., Nestle Health Science, Prometheus, QOL Medical, SK Life Science, Inc., Sucampo Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Valeant
Grants/Research Support: Ironwood Pharmaceuticals, Inc., Nestle Health Science, Prometheus
Other Financial Material Support: Co-CSO, My Total Health
This program is not affiliated with Digestive Disease Week®.
Supported by educational grants from Commonwealth Laboratories, LLC., and QOL Medical, LLC.
Provided by:
Stanley A. Cohen, MD, is a recognized expert in pediatric gastroenterology and nutrition. He received his undergraduate degree from Case Western Reserve University and his medical degree from Ohio State in his hometown of Columbus. His internship and residency were at Johns Hopkins Hospital. After serving as an Air Force physician, Dr. Cohen specialized in pediatric gastroenterology and nutrition with a fellowship at Harvard University and the Massachusetts General Hospital. During this time he also served as Director of Pediatrics at the Massachusetts Rehabilitation Hospital.
Dr. Cohen created The Center for Pediatric Gastroenterology and Nutrition, PC (CPGN) to better serve the needs of the children of the Southeast region. This has evolved into the Children's Center for Digestive Health Care, which now sees more patients with gastrointestinal, liver and nutritional problems than any other organization world-wide.
Dr. Cohen is also respected for his research and contributions to medical literature. In addition to over 150 abstracts and articles, Dr. Cohen edited two textbooks for physicians including The Underweight Child and wrote a previous book for parents: Healthy Babies, Happy Kids: A Common Sense Guide to Nutrition for Growing Years. This popular book was syndicated by United Press and republished in London as Start Right.
Dr. Cohen was the founding chairman of the Committee on Nutrition for the Georgia Chapter of the American Academy of Pediatrics. He was chairman of the Physicians Advisory Board of The Georgia WIC Program and was able to save the program over 50 million dollars which was then able to be directed to further care for the women and children in the state. He served as the first section chief for the pediatric subspecialists in the state, appointed by the Georgia Chapter of the AAP. He is proud to remain an active member of the staff at Children's Healthcare of Atlanta, and founded the Children's Digestive Research Fund under its stewardship to support important investigations in the areas of nutrition and gastrointestinal illnesses. He was recognized by the Atlanta Alliance on Developmental Disabilities for his work on nutrition and feeding for children with neurodevelopmental delays. In 1997, he received the national Lay Education Award from the American Academy of Pediatrics for his work to promote non abusive behaviors, with the curriculum he initiated in place in programs and school systems in the United States. And he was again recognized by that organization in 2012 for the nutritional algorithm that became the basis for What to Feed Your Baby: Cost-Conscious Nutrition for Your Infant.
In order to serve an even broader audience, Dr. Cohen and the father of one of his patients launched Nutrition4Kids.com, an innovative and interactive website designed to improve nutrition in North America. the Advisory Board that Dr. Cohen chairs includes prominent nutrition experts from around the country. Dr. Cohen has written over 100 articles and blogposts for the site and continues to oversee the information available to parents, including the age-appropriate nutrition content on 350,000 foods.
Dr. Cohen is a requested speaker at local, regional and national medical conferences and a consultant to nutritional, pharmaceutical and medical device companies. He is Adjunct Clinical Professor of Pediatrics at Emory University School of Medicine, is included in Who's Who in America, Who's Who in the World and Who's Who in Medicine and Healthcare, and has been featured on CNN, TBS and local television / radio. He was recognized by Turner Broadcasting in 2001 as one of Atlanta's "Super 17" for his contributions to the community. He has been listed as one of Atlanta Magazine's "Top Doctors" and in Consumers' Guide to Top Doctors in the US.
He is also known for his writing, having authored art reviews for Art Papers, a book review and Op Ed columns for the Atlanta Journal Constitution and numerous articles for parents in a variety of publications. One of his poems is bronzed in the courtyard of the Atlanta Fulton County Detention Center; others are included in various journals and in three self-published volumes. These volumes with accompanying art by Glenn Goldberg (Two), Gary Stephan (Seeping Into / Out of the Well) and Ed Ruscha (Beyond Hell) have entered the collections of prominent institutions including the Museum of Modern Art, the Whitney Museum and the Getty Museum. TheArtSection.com archived Cohen reading a number of his poems in 2012. Two of his most recent projects, Measured Words and Twisted Words reference his father's business, Esco Advertising Specialties, by replacing the traditional ad copy on wooden rulers with three line poems. These have been exhibited at Kibbee Gallery in Atlanta.
Grant/Research Support: AbbVie Inc., AstraZeneca, Covidien/Medtronics, Janssen,
QOL Medical
Consultant/Speaker Bureau: AbbVie Inc., AstraZeneca, Covidien/Medtronics, Janssen, Lupin, Nestles Institute, Nutricia, Prometheus, QOL Medical
Honorarium Recipient: AbbVie Inc., AstraZeneca, Janssen, Lupin, Nestlé Institute of Health Sciences, Nutricia, Prometheus, QOL Medical
Advisor/Shareholder: Nutrition 4 Kids
This program is not affiliated with Digestive Disease Week®.
Supported by educational grants from Commonwealth Laboratories, LLC., and QOL Medical, LLC.
Provided by:
Nicholas J. Talley, MD, is currently Pro Vice-Chancellor, Global Research at the University of Newcastle, Australia. He is an expert clinician, educator and researcher, with extensive experience as a leader in the medical and University sectors. He previously held an appointment as Pro Vice-Chancellor (and Dean) of the Faculty of Health and Medicine at the University of Newcastle from 2010-2015, and was seconded to be the Deputy Vice-Chancellor-Research (Acting) at the University of Newcastle from June 2013 to March 2014.
Professor Talley has published over 800 original and review articles in the peer-reviewed literature, and is considered one of the world's most influential clinician-researchers (H index 116, Scopus). He is also a leading medical educator and the author of the highly regarded textbooks Clinical Examination and Examination Medicine. In June 2014, Professor Talley was inaugurated as one of the first 15 Fellows of the Australian Academy of Health and Medical Sciences (FAHMS) and was elected to the Executive of the Academy.
At the end of 2015 Professor Talley will be stepping down from his role as Co-Editor-in-Chief of a major international journal Alimentary Pharmacology and Therapeutics after 6 years. This is the second major international Journal he has edited having completed two 3- year terms (the maximum permitted) as Co-Editor-in-Chief of the American Journal of Gastroenterology (12 years of consecutive international editing experience to date). Both journals thrived under his leadership substantially increasing their impact (and impact factor) and readership. He serves on a number of prominent boards and is a Section Editor for Up To Date, a management tool widely used by clinicians globally.
Professor Talley was formerly Chair of the Department of Internal Medicine at Mayo Clinic in Jacksonville, Florida where he held the rank of Professor of Medicine and Professor of Epidemiology, and was the Foundation Professor of Medicine at the University of Sydney, Nepean Hospital for nearly a decade.
Professor Talley is a Senior Staff Specialist and gastroenterologist at John Hunter Hospital and attends clinic and lists on a weekly basis. He currently holds adjunct research appointments as Professor at Mayo Clinic, University of North Carolina and the Karolinska Institute. He is a Fellow of the Royal Australasian College of Physicians (and President), the Royal College of Physicians (both London and Edinburgh), the American College of Physicians, the American College of Gastroenterology and the American Gastroenterological Association.
Other awards received include the Rome Foundation Board Lifetime Award, American Gastroenterological Association (AGA) Distinguished Educator Award, Newcastle Innovation Excellence in Innovation Award, NSW Excellence in Biological Sciences (Cell and Molecular, Medical and Veterinary and Genetics) Prize and the Distinguished Research Prize of the Gastroenterological Society of Australia.
Grants/Research Support: Abbott Pharmaceuticals, Janssen, Pfizer, Prometheus, Rome Foundation, Salix, a division of Valeant Pharmaceuticals North America LLC
Consultant/Speaker Bureau/Editorial Board Involvement: Adelphi values (functional dyspepsia working group to develop a symptom based PRO instrument), Allergens PLC, (GI Development Programs), GI therapies (non-invasive device company, consultant and options), Yuhan (IBS)
This program is not affiliated with Digestive Disease Week®.
Supported by educational grants from Commonwealth Laboratories, LLC., and QOL Medical, LLC.
Provided by:
Mark Pimentel, MD, is professor of medicine at Cedars-Sinai Medical Center in Los Angeles, California. Dr. Pimentel completed 3 years of an undergraduate degree in honors microbiology and biochemistry at the University of Manitoba, Canada. He received his medical degree and his BSc (Med) from the University of Manitoba Health Sciences Center in Winnipeg, Manitoba, Canada, where he also completed a residency in internal medicine.
Dr. Pimentel's medical training includes a fellowship in gastroenterology at the University of California, Los Angeles (UCLA) Affiliated Training Program. Active in research, Dr. Pimentel has served as a principal investigator or co-investigator for numerous basic science, translational, and clinical studies in such areas as irritable bowel syndrome and the relationship between gut flora composition and human disease.
Dr. Pimentel is a Diplomat of the American Board of Internal Medicine (Gastroenterology) and a Fellow of the Royal College of Physicians and Surgeons of Canada. He is also a member of several medical associations, including the American Gastroenterological Association, the American College of Gastroenterology, and the American Neurogastroenterology and Motility Society.
His work has been published in the New England Journal of Medicine, Annals of Internal Medicine, the American Journal of Physiology, The American Journal of Medicine, the American Journal of Gastroenterology, and Digestive Diseases and Sciences, among others. Dr. Pimentel has been invited to present his work at meetings, grand rounds, and advisory boards in the United States and internationally.
Grants/Research Support: Salix, a division of Valeant Pharmaceuticals North America LLC, Synthetic Biologics, Inc.
Consultant/Speaker Bureau: Salix, a division of Valeant Pharmaceuticals North America LLC, Synthetic Biologics, Inc.
Advisory Board Membership: Synthetic Biologics, Inc.
Stockholder: Synthetic Biologics, Inc., Naia Pharmaceuticals
Honorarium Recipient: Salix, a division of Valeant Pharmaceuticals North America LLC
Other Financial Material Support: Cedars-Sinai Medical Center has licensing agreements with Commonwealth Laboratories LLC, Naia Pharmaceuticasl, Salix, a division of Valeant Pharmaceuticals North America LLC, Synthetic Biologics, Inc.
This program is not affiliated with Digestive Disease Week®.
Supported by educational grants from Commonwealth Laboratories, LLC., and QOL Medical, LLC.
Provided by:
Philip S. Schoenfeld, MD, is professor of medicine and director of the training program in GI epidemiology at the University of Michigan School of Medicine in Ann Arbor. He is an expert in the management of irritable bowel syndrome (IBS), chronic constipation, gastroparesis, and pelvic floor disorders, and he sees patients in the University of Michigan Specialized Functional Bowel Disorder Clinic.
Dr. Schoenfeld completed his medical degree and his master's degree in medical education at the University of Pennsylvania in Philadelphia and his master's degree in clinical epidemiology at McMaster University in Hamilton, Ontario.
His research, which is funded by the National Institutes of Health and the US Department of Veterans Affairs, focuses on the treatment of IBS and chronic constipation, the application of evidence-based medicine to management of gastrointestinal disorders, and optimizing colon cancer screening with colonoscopy.
Dr. Schoenfeld is the editor of the Selected Summary Section of the journal Gastroenterology, past associate editor (colon section) of the American Journal of Gastroenterology, and has served on the editorial boards of the Journal of Clinical Gastroenterology, Alimentary Pharmacology and Therapeutics, and Gastroenterology & Hepatology. He is co-author of the American College of Gastroenterology Evidence-Based Position Statement on Management of Irritable Bowel Syndrome (2002) and its 2nd edition (2009), the American College of Gastroenterology Evidence-Based Position Statement on Management of Chronic Constipation (2005), the American College of Gastroenterology Guidelines for Colon Cancer Screening (2008), and the American Society for Gastrointestinal Endoscopy/American College of Gastroenterology Position Statement on Quality Indicators in Performance of Colonoscopy (In Press).
Consultant/Speaker Bureau: Allergan Pharmaceuticals, Ironwood Pharmaceuticals, Synergy Pharmaceuticals, Valeant Pharmaceuticals
Advisory Board Membership: Allergan Pharmaceuticals, Ironwood Pharmaceuticals, Synergy Pharmaceuticals, Valeant Pharmaceuticals
This program is not affiliated with Digestive Disease Week®.
Supported by educational grants from Commonwealth Laboratories, LLC., and QOL Medical, LLC.
Provided by:
© Copyright 2013-2025 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only.
Use of this website is governed by the GIHF terms of use and privacy statement.